(Total Views: 671)
Posted On: 07/01/2020 1:53:39 AM
Post# of 149078
If there were a licensing/buyout in the works, I would hope NP confirms this even if it means no details are given. It would be an equivalent counterpunch to the Citron BS.
I would wager an offer of around $35-$50 on good results. Sure no recurring revenues atm, but with a buttload of leronlimab on tap and CV19/HIV revenues expected to start this year, investors should consider this a growth company and price accordingly.
I would wager an offer of around $35-$50 on good results. Sure no recurring revenues atm, but with a buttload of leronlimab on tap and CV19/HIV revenues expected to start this year, investors should consider this a growth company and price accordingly.
(0)
(1)Scroll down for more posts ▼
